Hims & Hers Health shares gain more than 3% after reporting strong international expansion and new deal announcements

Traders Union
All News
Stocks
Hims & hers surges 3.29% today

Highlights

Hims & Hers Health reported third-quarter 2026 revenue of $890.4 million, up 49% year-over-year with growth supported by international expansion and new product partnerships.
The company posted a net loss of $33 million compared to prior-year profit, missed both revenue and earnings estimates, and narrowed full-year guidance to $3.13 to $3.15 billion with profitability pressured by higher branded product costs and expansion spending.
Shares of Hims & Hers Health last traded at $19.77 after a 3.29% daily gain, trading below key moving averages with momentum signals negative and a 79% probability of a downward move within the $15.82 to $23.72 forecast range.

Net loss returns as gains offset by higher costs and legal risks

Hims & Hers Health Inc reported third-quarter 2026 revenue of approximately $890.4 million, marking a 49% increase year-over-year, supported by international expansion, acquisitions, and new product partnerships in weight-loss treatments. Despite these gains, the company posted a net loss of $33 million compared to a prior-year profit and missed analysts’ estimates for both revenue and earnings. The full-year 2026 revenue outlook was narrowed to $3.13–$3.15 billion, with profitability pressured by higher branded product costs and expansion investments. The company also announced the upcoming launch of Peptides+ and noted ongoing legal and regulatory challenges, including a federal lawsuit and an FTC investigation into user data and subscription practices.

Anton Kharitonov, expert at Traders Union, sees little reason for optimism in Hims & Hers Health’s latest results. He notes that the stock’s position below all key moving averages and the negative momentum signals suggest entrenched bearish sentiment. The company’s sharp revenue growth is outweighed by a return to net loss, missed estimates, and a constrained outlook that exposes operational risks. Legal and regulatory issues add further downside risk to the investment case. "Investors should stay cautious and avoid chasing rebounds as the underlying technical and fundamental structure remains weak."

Viktoras Karapetjanc, expert at Traders Union, believes Hims & Hers Health is well positioned for longer-term growth. He points to strong revenue momentum, bold international expansion, and an ambitious new product pipeline that keeps the bullish structure intact. While immediate profitability is pressured, investments in scale and customer reach lay the groundwork for future gains. Macro trends and continued innovation offer further upside potential in coming quarters. "With forward-looking strategic moves and international growth, I see multiple setups for further appreciation in HIMS."

Parshwa Turakhiya, analyst, notes that technical signals for Hims & Hers are mixed but hint at a tactical trading window. Oversold RSI and Stochastic readings point to the possibility of a short-term bounce, even as momentum and trend strength remain weak. News-driven volatility and sentiment should drive quick shifts, especially near the $18.42–$22.12 range. "I see a setup for range-based trading—watch for sharp moves if either boundary is breached."

Bearish momentum persists amid oversold signals and volatility

Hims & Hers Health is trading below the MA-20 ($27.00), MA-50 ($28.10), and MA-200 ($26.81), indicating a bearish structure across short-, medium-, and long-term trends. The near-term ceiling is at $22.12 and the near-term floor at $18.42, though the MA-50's position above the MA-200 confirms a bullish long-term trend. Momentum signals remain negative, as the MACD shows a sell reading, while the ADX is neutral, reflecting weak trend strength. RSI, Stochastic RSI, and CCI are all in oversold zones, signaling a potential for an upside rebound. Bull/Bear Power (BBP) is negative, intraday momentum remains with sellers, and the Awesome Oscillator supports a bearish tone. The price currently sits mid-range for the session, with intraday volatility at 20.09%.

Previously it was reported that Hims & Hers faced persistent downside pressure following weaker-than-expected earnings and heightened regulatory uncertainty. The latest data reinforce a cautious outlook, as volatility remains elevated and traders should monitor the $18.42 support level for indications of further downside risk.

Source of Data: HIMS Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.